The University of Nottingham
  • Print
  

Treating Pyoderma Gangrenosum - More information from the STOP GAP Trial

The STOP GAP trial continues to make an impact regarding treatments for Pyoderma Gangrenosum.  A further three publications are now published which provide greater insight on this painful and debilitating disease.

1.  Is speed of healing a good predictor of eventual healing of pyoderma gangrenosum?

Wilkes SR, Williams HC, Ormerod AD, Craig FE, Greenlaw N, Norrie J, Mitchell EJ, Mason JM, Thomas KS; United Kingdom Dermatology Clinical Trials Network STOP GAP team.
J Am Acad Dermatol. 2016 Oct 11. pii: S0190-9622(16)30601-6. doi: 10.1016/j.jaad.2016.07.049.

2. Clinical outcomes and response of patients applying topical therapy for pyoderma gangrenosum

Clinical outcomes and response of patients applying topical therapy for pyoderma gangrenosumThomas KS, Ormerod AD, Craig FE, Greenlaw N,  Norrie J, Mitchell E, Mason JM, Johnston GA, Wahie S, and Williams HC on behalf of the UK Dermatology Clinical Trials Network’s STOP GAP team Clinical outcomes and response of patients applying topical therapy for pyoderma gangrenosum: a prospective cohort study. 2016 JAAD 75 (5) 940-949 doi:10.1016/j.jaad.2016.06.016

3.  Comparison of the two most commonly used treatments for pyoderma gangrenosum: results of the STOP GAP randomised controlled trial

Ormerod AD, Thomas KS, Craig FE, Mitchell E, Greenlaw N, Norrie J, Mason JM, Walton S, Johnston GA and Williams HC on behalf of the UK Dermatology Clinical Trials Network’s STOP GAP team. Prednisolone versus ciclosporin for the treatment of pyoderma gangrenosum: STOP GAP randomized controlled trial. BMJ 2015;350:h2958. doi: http://dx.doi.org/10.1136/bmj.h2958

Posted on Monday 24th October 2016

UK Dermatology Clinical Trials Network


Centre of Evidence Based Dermatology
The University of Nottingham King's Meadow Campus, Rm A103
Lenton Lane, Nottingham
NG7 2NR, UK

Email: UKDCTN@nottingham.ac.uk